サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138385

ぶどう膜炎治療の世界市場-2022-2029

Global Uveitis Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ぶどう膜炎治療の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

主な原動力は、ぶどう膜炎の発症率の上昇、助成金やフェローシップの存在、研究開発活動の活発化です。

研究開発活動の高まりは、世界市場の成長を後押ししています。

目の炎症治療のための臨床試験の数が増加しており、例えば、臨床試験によると、世界的に実施されています。例えば、ルーヴェン大学（Universitaire Ziekenhuizen Leuven）がスポンサーを務め、2023年1月1日に完了予定の免疫抑制治療としてのバードショットぶどう膜炎に対するアバタセプトの効率性と安全性を評価する試験、ワシントン大学医学部がスポンサーを務める炎症性眼疾患に対するTofacitinibに関する試験など、現在5種類の試験がぶどう膜炎に対する介入に活発に取り組まれています。Vastra Gotaland Regionがスポンサーとなり、2022年12月に終了が予測されるぶどう膜炎の患者さんにおける疎水性および親水性眼内レンズの使用成績に焦点を当てた試験、天津医科大学のXiaomin Zhangがスポンサーとなり、2022年12月に終了が予測される難治性小児ぶどう膜炎の患者さんにinfliximabが臨床的に有用であるという仮説を検証する第4相試験などがあります。さらに、35の臨床試験が募集されており、世界市場の将来的な成長を示しています。

高いコスト、薬の副作用の可能性、厳しい規制は、世界のぶどう膜炎治療市場の成長を阻害する理由となるでしょう。

しかし、高価格、薬剤に伴う副作用、眼疾患に関する知識不足が市場成長を抑制すると予想されます。また、涙目や炎症などの薬の副作用も、市場成長の妨げになると思われます。

産業分析

世界のぶどう膜炎治療市場レポートでは、Porter`s Five forces、研究開発、疫学、規制、価格、パイプライン分析など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

パンデミックの際、COVID-19の蔓延を抑えるために多くの制限が課されたため、世界市場はマイナスの影響を受け、需給チェーンが混乱し、ぶどう膜炎治療の売上を減少させることになりました。さらに、社会化規制により定期的な眼科検診を受けることが困難となり、ほとんどのぶどう膜炎患者が未検出となり、世界のぶどう膜炎治療剤市場にマイナスの影響を及ぼしました。

世界のぶどう膜炎治療市場レポートは、約40以上の市場データ表、45以上の図、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 成長する研究開発
      • ぶどう膜炎患者の増加
      • 市場戦略
    • 抑制要因
      • 高いコスト
      • 薬剤の副作用
      • 厳しい規制機関
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 疫学分析
  • 研究と開発
  • パイプライン分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 治療タイプ別

  • 副腎皮質ホルモン剤
  • 免疫抑制剤
  • モノクローナル抗体
  • 抗生物質
  • その他

第8章 疾患タイプ別

  • 前部ぶどう膜炎
  • 後方ぶどう膜炎
  • 中間ぶどう膜炎
  • 汎ぶどう膜炎

第9章 原因別

  • 非感染性
  • 感染性

第10章 販売チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第13章 企業プロファイル

  • Bausch & Lomb Incorporated
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Santen Pharmaceutical Co., Ltd
  • AbbVie Inc.
  • Eyegate Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals
  • Eyepoint Pharmaceuticals Inc.
  • Alimera Sciences, Inc.
  • Clearside Biomedical, Inc.
  • Aldeyra Therapeutics, Inc

第14章 DataM

目次
Product Code: DMPH2170

Market Overview

Uveitis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Uveitis is an inflammation of the middle layer of an eye (uvea), also known as the uveal tract. Auto-immune disorders, injuries, inflammatory disorders, infections, and surgeries are common causes of uveitis. Common symptoms of uveitis include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye.

Market Dynamics

The major driving forces are the rising incidence of uveitis, the presence of grants and fellowships, growing research and development activities.

The growing research and development activities are fueling the global market growth.

An increasing number of clinical trials for eye inflammation treatment are being conducted globally, for instance, according to the clinical trials. Gov currently, five different clinical trials are actively working on intervention for Uveitis, such as a study to estimate the efficiency and safety of Abatacept for Birdshot uveitis as an immunosuppressive treatment sponsored by Universitaire Ziekenhuizen Leuven and estimated completion on January 1, 2023, a study on Tofacitinib for the treatment of inflammatory eye disease sponsored by Washington University School of Medicine, a study focused on the outcome with the hydrophobic and hydrophilic intraocular lens in patients with and without uveitis sponsored by Vastra Gotaland Region and estimated completion on December 2022 and a phase 4 study to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis sponsored by Xiaomin Zhang, Tianjin Medical University and predicted completion by December 2022. Furthermore, 35 more clinical studies are recruiting, indicating the global market's future growth.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global Uveitis Treatment market growth.

However, the high prices, the side effects associated with the medications, and the lack of knowledge regarding eye disorders are expected to restrain the market growth. Also, the side effects of medications like watery eyes and irritation will likely hamper the market growth.

Industry analysis.

The global uveitis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

During the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of Uveitis Treatment. Furthermore, the socializing restriction made it difficult to get regular eye checkups, leaving most uveitis patients undetected, negatively impacting the global uveitis treatment market.

Segment Analysis

Corticosteroids are presumed to be prevailing throughout the forecast period (2022-2029)

The corticosteroid segment is expected to grow at a high rate since it is considered the mainstay treatment for patients with non-infectious uveitis. Corticosteroid drugs are very useful in minimizing inflammation. The FDA approved several corticosteroid eye drops available on the market. Ophthalmologists generally recommend eye drops, oral medications, or injections of corticosteroids. Corticosteroid implant is also increasingly gaining traction for people with chronic eye inflammation disorders. For instance, Retisert of Bausch+Lomb is the US's first FDA-approved surgical corticosteroid implant for treating non-infectious posterior uveitis. Many novel clinical trials are developing for uveitis. For instance, a phase 2 trial for the efficiency and safety of the Interleukin-17A inhibitor Izokibep (ABY-035) for treating a non-infectious intermediate, posterior or pan-uveitis (LINNAEA) sponsored by ACELYRIN Inc. and estimated to be complete by November 2022 and clinical study on Abatacept in Patients With Birdshot HLA A29 Uveitis: a phase II prospective 0pen label interventional proof-of-concept study sponsored by Universitaire Ziekenhuizen Leuven and estimated to be completed by January 1, 2023.

Geographical Analysis

The North American region is overshadowing the global uveitis treatment market.

North America dominated the Uveitis Treatment market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase of approximately 15 cases per 100,000 population annually or some 38,000 new cases annually. It is a significant cause of blindness, accounting for 10-15% of all blindness in the United States, costing approximately $242 million annually. Furthermore, the NIH states that Uveitis is very common in the geriatric population and as the American geriatric population is growing at a high rate is contributing to its dominance over the market. For instance, as per the estimation from the U.S. Census Bureau, more than 56 million American adults aged 65 and older in the United States account for about 16.9% of the nation's population. By 2030, when the last person from the boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults.

Competitive Landscape

Competitive Landscape

The major players operating in the global uveitis treatment market are Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd, AbbVie Inc., Eyegate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences, Inc., Clearside Biomedical, Inc., and Aldeyra Therapeutics, Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the uveitis treatment market globally. For instance, on May 8, 2020, AbbVie Inc. acquired Allergan plc. Also, on JUNE 2, 2022, Bausch + Lomb announced Launched Biotrue Hydration Plus, a multi-purpose solution.

Bausch + Lomb

Overview

Bausch + Lomb is a leading eye health products manufacturing company headquartered in Canada and was founded in 1853. It is among the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. Bausch + Lomb, on May 6, 2022, became a publicly traded company in 2021; around 21,000 employees were working for Bausch + Lomb.

Product Portfolio

Bausch + Lomb Company's uveitis product portfolio has XIPERE, VISUDYNE and RETISERT.

The global uveitis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Research and Development
      • 4.1.1.2. Growing Cases of Uveitis
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Drug Side Effects
      • 4.1.2.3. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Corticosteroids
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Immunosuppressant
  • 7.4. Monoclonal Antibodies
  • 7.5. Antibiotics
  • 7.6. Others

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 8.1.2. Market Attractiveness Index, By Disease Type Segment
  • 8.2. Anterior Uveitis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Posterior Uveitis
  • 8.4. Intermediate Uveitis
  • 8.5. Panuveitis

9. By Cause

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
    • 9.1.2. Market Attractiveness Index, By Cause Segment
  • 9.2. Non-Infectious
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious

10. By Distribution Channels

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 10.2. Hospital Pharmacies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bausch & Lomb Incorporated
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Santen Pharmaceutical Co., Ltd
  • 13.3. AbbVie Inc.
  • 13.4. Eyegate Pharmaceuticals, Inc.
  • 13.5. Regeneron Pharmaceuticals
  • 13.6. Eyepoint Pharmaceuticals Inc.
  • 13.7. Alimera Sciences, Inc.
  • 13.8. Clearside Biomedical, Inc.
  • 13.9. Aldeyra Therapeutics, Inc

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact